Interested in finding out more about OMOP, below is a list of publications.

Published online before print
Stang PE, Ryan PB, Dusetzina SB, Hartzema AG, Reich C, Overhage JM, & Racoosin JA. Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. Health Outcomes Research in Medicine (2011). doi: 10.1016/j.ehrm.2011.11.003

Overhage JM, Ryan PB, Reich CG et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54-60. Epub 2011 Oct 28.

Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):292-9. doi: 10.1002/pds.2051. Epub 2010 Oct 13.

Murray RE, Ryan PB, & Reisinger SJ. (2011). Design and Validation of a Data Simulation Model for Longitudinal Healthcare Data. AMIA Annu Symp Proc., USA, 2011: 1176–1185.

Published online before print
Zorych I, Madigan D, Ryan P, and Bate A. Disproportionality methods for pharmacovigilance in longitudinal observational databases.
Stat Methods Med Res, August 30, 2011 as doi:10.1177/0962280211403602.

Madigan D, Ryan P. What can we really learn from observational studies? The need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research. Epidemiology. 2011;22:629–631.

Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 2;153(9):600-6.

Ryan PB, Welebob E, Hartzema AG, Stang PE, Overhage JM. Surveying US observational data sources and characteristics for drug safety needs. Pharm Med. 2010; 24 (4): 231-238.